Scotia Capital’s Jade Biosciences JBIO Stock Holding History

Scotia Capital’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,063	Closed	-$98.6K	–	851
2024 Q4	$98.6K	Buy	+1,063	New	+$91.6K	﹤0.01%	820

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Allostery Investments Stamford, Connecticut $7.85M AUM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Scotia Capital's JBIO Position: Q1 2025 in Review

Scotia Capital sold out of Jade Biosciences (JBIO) in Q1 2025, closing a stake of 1,063 shares — an estimated $98.6K sold.

Scotia Capital first reported a position in JBIO in Q4 2024 and held it in 1 quarter. The position peaked at $98.6K in Q4 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q1 2025.

Scotia Capital reported no remaining Jade Biosciences position as of Q1 2025 after selling out during the quarter.
Scotia Capital sold 1,063 Jade Biosciences shares in Q1 2025, an estimated $98.6K.
Scotia Capital first reported a position in Jade Biosciences in Q4 2024 and held it in 1 quarter.
Scotia Capital's Jade Biosciences position peaked at $98.6K in Q4 2024.
78 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2025.

Based on Scotia Capital's 13F filing for Q1 2025, filed 9 May 2025.